CAS 162635-04-3
:Temsirolimus
Description:
Temsirolimus is an antineoplastic agent primarily used in the treatment of renal cell carcinoma. It is a derivative of rapamycin and functions as an inhibitor of the mammalian target of rapamycin (mTOR), a key regulator of cell growth, proliferation, and survival. Temsirolimus is characterized by its ability to interfere with the signaling pathways that promote tumor growth, making it effective in certain types of cancer. The compound is typically administered intravenously and is known for its pharmacokinetic properties, including a relatively long half-life, which allows for sustained therapeutic effects. Its solubility profile is moderate, and it is often formulated with specific excipients to enhance its bioavailability. Common side effects associated with temsirolimus include fatigue, nausea, and potential immunosuppression, necessitating careful monitoring during treatment. Overall, temsirolimus represents a targeted therapeutic approach in oncology, particularly for patients with advanced renal cell carcinoma who may benefit from mTOR inhibition.
Formula:C56H87NO16
InChI:InChI=1/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
InChI key:InChIKey=CBPNZQVSJQDFBE-FUXHJELOSA-N
SMILES:O=C1N2[C@](C(=O)O[C@]([C@@H](C[C@H]3C[C@@H](OC)[C@H](OC(C(CO)(CO)C)=O)CC3)C)(CC(=O)[C@H](C)/C=C(\C)/[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@@H](OC)C[C@]4(O[C@@](O)(C1=O)[C@H](C)CC4)[H])[H])(CCCC2)[H]
Synonyms:- (1R,2R,5S)-5-{(2S)-2-[(3S,6R,7E,9R,10R,12R,14S,15Z,17E,19E,21S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
- 4-{2-[(7E,15Z,17E,19E)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
- 40-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin
- Cci 779
- Ccl-779
- NSC 683864
- Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate
- Temsorolimus
- Torisel
- Way-Cci 779
- Temsirolimus
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 11 products.
Temsirolimus
CAS:Formula:C56H87NO16Purity:>95.0%(HPLC)Color and Shape:White to Almost white powder to crystalMolecular weight:1,030.30Temsirolimus
CAS:<p>Temsirolimus (CCI-779) is a specific mTOR inhibitor ( IC50: 1.76 μM), used in the treatment of advanced renal cell cancer.</p>Formula:C56H87NO16Purity:97.76% - >99.99%Color and Shape:White Crystalline PowderMolecular weight:1030.29Temsirolimus-d3
CAS:Controlled Product<p>Applications Labelled ester analog of Rapamycin.<br>References Raymond, E., et al.: J. Clin. Oncol., 22, 2336 (2004), Galanis, E., et al.: J. Clin. Oncol., 23, 5294 (2005)<br></p>Formula:C56H84D3NO16Purity:>85%Color and Shape:NeatMolecular weight:1033.31Temsirolimus (~90%)
CAS:Controlled Product<p>Applications Ester analog of Rapamycin.<br>References Raymond, E., et al.: J. Clin. Oncol., 22, 2336 (2004), Galanis, E., et al.: J. Clin. Oncol., 23, 5294 (2005)<br></p>Formula:C56H87NO16Purity:>80%Color and Shape:NeatMolecular weight:1030.29Temsirolimus
CAS:<p>mTOR serine/threonine kinase inhibitor</p>Formula:C56H87NO16Purity:Min. 95%Color and Shape:PowderMolecular weight:1,030.29 g/molTemsirolimus-13C3,d7
CAS:Controlled ProductFormula:C3C53D7H80NO16Color and Shape:NeatMolecular weight:1040.308







